Literature DB >> 7094989

The influence of blood collection technique on serum and plasma protein binding of disopyramide.

D B Haughey, J J Lima.   

Abstract

Serum and plasma disopyramide (D) protein binding was compared after blood was collected from four normal subjects in various Vacutainer tubes. The fraction of disopyramide bound to proteins in control serum and plasma was drug concentration dependent and correlated well with the capacity factor (N) associated with a high affinity protein binding site. D free fraction increased 60% at a postequilibrium concentration of 2 micrograms/ml in plasma following exposure of blood to green-top Vacutainer stoppers due to a 60% reduction in the affinity constant associated with the high affinity protein binding site. Heparin and EDTA had no effect on the plasma protein binding of D. These results suggest a competitive inhibition of disopyramide binding to alpha 1-acid-glycoprotein following contact of blood with rubber Vacutainer stoppers.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7094989     DOI: 10.1007/BF00542466

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  A graphic method for the determination and presentation of binding parameters in a complex system.

Authors:  H E Rosenthal
Journal:  Anal Biochem       Date:  1967-09       Impact factor: 3.365

2.  Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.

Authors:  P H Hinderling; E R Garrett
Journal:  J Pharmacokinet Biopharm       Date:  1976-06

3.  Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation.

Authors:  K M Piafsky; O Borgå
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

4.  Role of concentration-dependent plasma protein binding in disopyramide disposition.

Authors:  P J Meffin; E W Robert; R A Winkle; S Harapat; F A Peters; D C Harrison
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

5.  Protein binding of several drugs in serum and plasma of healthy subjects.

Authors:  U W Wiegand; K L Hintze; J T Slattery; G Levy
Journal:  Clin Pharmacol Ther       Date:  1980-03       Impact factor: 6.875

6.  Contamination of albumin by alpha 1-acid glycoprotein.

Authors:  J J Lima; L B Salzer
Journal:  Biochem Pharmacol       Date:  1981-09-15       Impact factor: 5.858

7.  Plasma protein binding of basic drugs. I. Selective displacement from alpha 1-acid glycoprotein by tris(2-butoxyethyl) phosphate.

Authors:  O Borgå; K M Piafsky; O G Nilsen
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

8.  Blood collection techniques, heparin and quinidine protein binding.

Authors:  K M Kessler; R C Leech; J F Spann
Journal:  Clin Pharmacol Ther       Date:  1979-02       Impact factor: 6.875

9.  Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.

Authors:  J J Lima; H Boudoulas; M Blanford
Journal:  J Pharmacol Exp Ther       Date:  1981-12       Impact factor: 4.030

10.  Importance of blood-collection tubes in plasma lidocaine determinations.

Authors:  W W Stargel; C R Roe; P A Routledge; D G Shand
Journal:  Clin Chem       Date:  1979-04       Impact factor: 8.327

View more
  6 in total

1.  Potential applications of free drug level monitoring in cardiovascular therapy.

Authors:  R L Woosley; L A Siddoway; K Thompson; I Cerskus; D M Roden
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of disopyramide.

Authors:  A Karim; C Nissen; D L Azarnoff
Journal:  J Pharmacokinet Biopharm       Date:  1982-10

3.  Disopyramide protein binding in plasma from patients with nephrotic syndrome during the exacerbation and remission phases.

Authors:  H Echizen; S Saima; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

4.  Inhibitory effect of free fatty acids on plasma protein binding of disopyramide in haemodialysis patients.

Authors:  T Horiuchi; I Johno; T Hasegawa; S Kitazawa; M Goto; T Hata
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 5.  Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

6.  The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies.

Authors:  R A Upton; R L Williams
Journal:  J Pharmacokinet Biopharm       Date:  1986-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.